Loading your page…
Kidney and Dialysis
By Tan Huynh Ngoc Mai, Linh Thi Thao Nguyen, Dat Hoang Phan and 1 others.
Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in multiple complications of end-stage renal disease. This study evaluated the predictive value of baseline plasma ET-1 for 18-month all-cause mortality in Vietnamese hemodialysis patients.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
A prospective cohort study enrolled 222 patients on maintenance hemodialysis. Plasma ET-1 concentrations were quantified using an enzyme-linked immunosorbent assay (ELISA). The primary endpoint was 18-month all-cause mortality. Predictive accuracy was evaluated using receiver operating characteristic (ROC) curves, Kaplan–Meier survival analysis, and Cox proportional hazards regression models.
During the 18-month follow-up, 57 patients (25.68%) died. Non-survivors exhibited significantly higher median ET-1 levels compared to survivors (131.08 vs. 46.69 pg/mL, p < 0.001). The optimal ET-1 cutoff for predicting mortality was 85.06 pg/mL (area under the curve [AUC] = 0.875). Kaplan–Meier analysis demonstrated significantly worse survival in patients with ET-1 > 85.06 pg/mL (log-rank p < 0.001). In a multivariable Cox regression model adjusted for age, apparent treatment-resistant hypertension (aTRH), diabetes mellitus, and heart failure using a forward stepwise selection method, log2-transformed ET-1 remained a significant and independent predictor of all-cause mortality (hazard ratio [HR], 2.06; 95% confidence interval [CI], 1.52–2.79; p < 0.001).
Baseline plasma ET-1 was independently associated with 18-month all-cause mortality in this single-center cohort of Vietnamese patients receiving maintenance hemodialysis. External validation is required before ET-1 can be recommended for routine clinical risk stratification.
Published in Kidney and Dialysis. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
